Abstract

As part of a larger literature study on transgenic animals in mutagenicity testing, test results from the transgenic mutagenicity assays (*lacI* model; commercially available as the Big Blue® mouse, and the *lacZ* model; commercially available as the Muta™Mouse), were compared with the results on the same substances in the more traditional mouse bone marrow micronucleus test. 39 substances were found which had been tested in the micronucleus assay and in the above transgenic mouse systems. Although, the transgenic animal mutation assay is not directly comparable with the micronucleus test, because different genetic endpoints are examined: chromosome aberration versus gene mutation, the results for the majority of substances were in agreement. Both test systems, the transgenic mouse assay and the mouse bone marrow micronucleus test, have advantages and they complement each other. However, the transgenic animal assay has some distinct advantages over the micronucleus test: it is not restricted to one target organ and detects systemic as well as local mutagenic effects.

Background

This and the following presentation are part of a project for the International Programme on Chemical Safety (IPCS) evaluating the possible use of transgenic animal mutagenicity assays in chemical toxicity testing and mechanistic research. It was decided to compare the results obtained from those transgenic mutagenicity test systems where considerable data was available, with other in vivo genotoxicity tests: in the first article (Part I) with the mouse bone marrow micronucleus test and in the second (Part II) with the mouse spot test.

The mouse bone marrow micronucleus test is one of several available *in vivo* mammalian test system for the detection of chromosomal aberrations [1-5]. A documentation of the test procedure and evaluation of results is given in the OECD guideline 474 [6]. This test is routinely used with a widespread acceptance in industry and authorities.

Mutagenicity assays using transgenic animals have been developed in particular the *lacI* model [7] (commercially available as the Big Blue® mouse), and the *lacZ* model [8] (commercially available as the Muta™Mouse). In this article, available data on the results of mouse bone marrow micronucleus test were compared with results from these two transgenic mouse assays for 39 substances. The advantages and disadvantages of the test systems are discussed. Recently, further transgenic rodent mutation assays have been developed, however, the data base is not sufficient for comparison with other test systems.
The mouse bone marrow micronucleus test: principles and procedure

Micronuclei are chromatin-containing bodies in the cytoplasm arising from acentric chromosome fragments or from whole chromosomes that were not incorporated in the daughter nuclei during the last stages of mitosis. Chromosome fragments are associated with the clastogenic (chromosome breakage) activity of the test substance whereas the presence of a whole chromosome is indicative of an adverse effect of the test substance on the mitotic spindle apparatus (aneugenic effects). The difference in size of the micronucleus is therefore an indicator for clastogenicity (small micronucleus) or aneugenicity (large micronucleus). However, the size of the micronucleus is an inaccurate measure. Micronuclei can be distinguished by further criteria, for example by identification of the presence of a kinetochore or centromeric DNA, indicating aneugenic activity. Overall, an increase in micronuclei is an indirect measure of induced structural or numerical chromosome aberrations [1,2].

In the micronucleus test according to the OECD guideline 474, erythroblasts in the bone marrow of mice (or rats) are used as target cells. When a bone marrow erythroblast develops into a polychromatic erythrocyte, the main nucleus is extruded. Any micronucleus that has been formed may remain in the otherwise anucleated cytoplasm and can easily been detected. An increase in the frequency of micronucleated polychromatic erythrocytes in treated animals is an indication of induced chromosome damage [6].

In the last three decades, toxicologists have often used the mouse bone marrow micronucleus test because 1) it is part of the regulatory toxicology in the admission procedure for chemicals and drugs and 2) it has advantages in speed, simplicity, and cost effectiveness in comparison to other in vivo systems for testing chromosomal aberrations (e.g. the cytogenetic test).

Transgenic mouse models

Transgenic mutation test systems contain a foreign gene construct having two essential parts: the transgene containing the target gene that serves as target for mutations, and a shuttle vector for recovering the target gene DNA from the tissue of the transgenic animal. The transgene is constructed using recombinant DNA technologies.

LacZ transgenic mouse model (Big Blue® mouse)
The proprietary mouse of the Big Blue® mutagenesis assay system contains about 30–40 copies of a lambda LIZα shuttle phage vector integrated into its genome at a single locus on chromosome 4. The target site for mutagenesis is the lacI gene [7].

The test compound is administered to the mouse either as a single or repeated dose. After the post treatment period for manifestation of the DNA lesions, the tissue of interest is isolated and the DNA extracted. A proprietary lambda DNA packaging extract automatically excises the lambda vector target and packages it into a lambda phage head and the phage is transfected to bacteria. These bacteria are plated on agar indicator plates containing the chromogenic substance (X-gal). The phage transfected bacteria with mutations in the lacI gene form blue plaques, whereas bacteria with a nonmutated lacI form colourless plaques. The ratio between blue and white plaques is a measure of the mutagenicity. [7,9].

LacZ transgenic mouse model (Muta™Mouse)
The lambda-gt10-lacZ shuttle vector for the lacZ mouse model contains the entire lacZ target gene [8]. The commercially available lacZ mouse model contains about 80 copies of the shuttle vector at chromosome 3.

As above, the test compound is administered to the mouse, the genomic DNA is isolated from the tissue of interest, and the lambda genomes are excised by and packed with a bacteriophage packaging extract. The resulting phage particles are then plated on a lacZ: E. coli strain (for transfection) in the presence of the chromogenic substance (X-gal) as indicator. The plaques containing an intact lacZ are β-galactosidase active and are blue, whereas plaques containing mutated lacZ will be white/colourless. In this original model the ratio between colourless and blue plaques is a measure of the mutagenicity. Due to optical difficulties in the evaluation of plaques, this system has been improved using a selection assay in lieu of colour screening whereby only mutant particles form plaques [10]. The number of plaques under non-selective conditions is a measure for the total number of phage-transfected bacteria (intact or mutant lacZ gene). The ratio between the number of plaques produced under selective conditions versus the number of plaques under non-selective conditions is a measure of the mutagenicity [9,10].

Methods

Data presented in this documentation are the results of an extensive literature research. Concerning data on transgenic mouse assays only primary literature was used. Data on the mouse bone marrow micronucleus assay were extracted from reliable reviews on this item or from primary literature. For all other data informations from secondary literature or data compilation bases were used.

Results and Discussion

Comparison of data from the mouse bone marrow micronucleus test and transgenic mouse test

The authors are aware that a comparison of the transgenic mouse assays with the mouse bone marrow micronucleus...
test is limited by the fact that different genotoxic endpoints are studied in these two systems. In transgenic mouse assays, point mutations and small insertions and deletions are detected whereas in the mouse bone marrow assay, chromosome breakage leading to light microscopically visible micronuclei resulting from chromosome fragment or micronuclei originating from whole chromosomes are investigated. However, both point mutations and micronuclei may be induced by a single agent, so some overlap of results is to be expected.

From the literature, 39 substances were identified with data on the mouse bone marrow micronucleus test and the Muta™ mouse assay (n = 29) or the Big Blue® mouse assay (n = 21) or both transgenic mutation assays (n = 11); see Additional file 1 for references. Agreement between the Muta™ mouse and the micronucleus test was seen with 18 out of 29 substances, no agreement with 8 substances and in 3 cases the comparison is inconclusive because of questionable results in the micronucleus assay. With the Big Blue® mouse assay, the results obtained with 14 out of 21 substances agreed with results in the mouse micronucleus test, but 6 showed no agreement and another was inconclusive.

Most substances included in this comparison are also carcinogenic in long-term assays on mice. No data on carcinogenicity in mice are available for 4-acetylaminofluorene and negative results were obtained with bromomethane and 2,6-diaminotoluene.

**Carcinogenic substances with positive results in the bone marrow micronucleus and transgenic gene mutation assays**

**Studies with Muta™ mouse**

The following 17 substances were gene mutagenic in at least one of the examined organs in the Muta™ mouse assay, induced micronuclei in mouse bone marrow and showed positive results in carcinogenicity studies on mice: 2-acetylaminofluorene, 4-aminobiphenyl, benzo(a)pyrene, 1,3-butadiene, chlorambucil, cyclophosphamide, 7,12-dimethylbenz(a)anthracene, ethylene oxide, N-ethyl-N-nitrosourea, N-methyl-N-nitrosourea, N-nitrosodimethylamine, urethane. In the Big Blue® mouse assay the target organ bone marrow revealed also increased mutation frequencies induced by benzene, 1,3-butadiene, and 7,12-dimethylbenz(a)anthracene. However, negative results in bone marrow were obtained with cyclophosphamide, ethylene oxide, and N-nitrosodimethylamine, indicating that other target organs are more sensitive in the Big Blue® mouse assay. All of these 12 substances induced also chromosome aberrations in majority of further in vivo and in vitro studies.

**Studies with Big Blue® mouse**

12 substances showed gene mutagenic effects in at least one of the examined organs in the Big Blue® mouse assay, chromosome mutagenic effects in the mouse bone marrow micronucleus assay and induced carcinogenic effects in long-term assays on mice: 2-acetylaminofluorene, aflatoxin B1, benzene, benzo(a)pyrene, 1,3-butadiene, cyclophosphamide, 7,12-dimethylbenz(a)anthracene, ethylene oxide, N-ethyl-N-nitrosourea, N-methyl-N-nitrosourea, N-nitrosodimethylamine, urethane. In the Big Blue® mouse assay the target organ bone marrow revealed also increased mutation frequencies induced by benzene, 1,3-butadiene, and 7,12-dimethylbenz(a)anthracene. However, negative results in bone marrow were obtained with cyclophosphamide, ethylene oxide, and N-nitrosodimethylamine, indicating that other target organs are more sensitive in the Big Blue® mouse assay. All of these 12 substances induced also chromosome aberrations in majority of further in vivo and in vitro studies.

**Substances with carcinogenic effects in mice but no agreement between the transgenic mouse assay and the mouse bone marrow assay**

**Acrylamide**

The inconclusive result in the bone marrow micronucleus test [4] is contradictory to the Muta™ mouse assay [21-23] which shows mutagenic activity in the target organ bone marrow but also contradictory to other in vivo tests on the endpoint chromosome aberration including a cytogenetic test on mice [4,19,21]. Micronuclei were detected in spleen and testis of mice [4]. Overall, using other experimental design the mouse bone marrow micronucleus assay might give clearly positive results.

**2-Amino-3-methylimidazo(4,5-f)quinoline (IQ)**

IQ is mutagenic in the liver of the Muta™ mouse [34] but negative results were obtained in the mouse bone marrow micronucleus test [2,35]. This negative result is supported by a negative cytogenetic assay on mice. Inconclusive results were obtained in in vitro studies on chromosome aberrations but IQ induced micronuclei in rats (see Additional file 1). This discrepancy might be due to the possibility that a) the liver but not the bone marrow of mice is target organ (the liver but not the blood is target organ in carcinogenicity [33]) or b) IQ is less clastogenic than gene mutagenic in mice.
ortho-Anisidine
The target organ of carcinogenesis in mice (and humans) is the bladder [36]. In the Big Blue™ assay on mice mutagenic activity was detected in the bladder but not in the liver [37]. As expected, the mouse bone marrow micronucleus test [4,36] gave negative results (also in rats; see Additional file 1), because the bone marrow is presumably not a target organ of mutagenicity.

Asbestos crocidolite
Local carcinogenic effects were observed in carcinogenicity studies, the lung is the target organ after inhalation [38-40]. Mutagenic activity was detected in the lung of Big Blue™ mice after inhalation [41]. As expected, clearly no systemic effects in the bone marrow could be observed in the mouse micronucleus test [4].

2,4-Diaminotoluene
The main target organ in carcinogenicity is the liver (also in rats) [81]. Positive results were reported in two Big Blue™ mouse assays examining the liver [82-84]. The mouse micronucleus test gave negative results [4], however, systemic effects in the bone marrow are not expected from carcinogenicity studies. Results of other studies on chromosome aberration in vivo are inconclusive (see Additional file 1).

Hydrazine
This substance induced no mutagenic effects in lung, liver, or bone marrow of the Muta™mouse which were target organs in mouse carcinogenicity studies [119,120]. The mouse bone marrow micronucleus test gave positive results after repeated application [4,119]. However, single exposure was used in the Muta™mouse assay [120]. Studies on other in vivo genotoxicity endpoints have shown almost negative results after single exposure but genotoxic activity after repeated application, for example in the mouse bone marrow micronucleus assay [4]. Positive results might be expected in the Muta™mouse assay using another experimental design since other in vivo as well as in vitro test systems revealed gene mutagenic effects.

Methyl methanesulfonate
Only weak mutagenic effects in the liver but no effects in bone marrow were observed in the Muta™mouse [18,124] and negative results in the Big Blue™ mouse [111-113,126]. In the mouse bone marrow micronucleus test this carcinogenic substance induced chromosome aberration [1,127]; other in vitro and in vivo assays clearly supported the clastogenic activity [121,122]. There is evidence that the chromosome mutagenic activity is detectable at much lower doses than the gene mutagenic activity. Tinwell et al. (1998) [18] have shown on Muta™mice a weak gene mutagenic effect in the liver but no effect in the bone marrow. The same dose induced in these animals a significant increase in bone marrow micronuclei indicating clear clastogenic activity. Overall, methyl methanesulfonate is more clastogenic than gene mutagenic.

Mitomycin C
A very similar situation is given with mitomycin C. No mutagenic activity was observed in the Muta™mouse assay in liver and bone marrow after single injection but the same dose induced chromosome aberrations in the bone marrow of the same mice [142]. The mouse bone marrow micronucleus test [1,47] and all in vivo and in vitro assays on the endpoint chromosome aberration revealed clearly positive results [139-141].

N-Nitrosodiethylamine
The main target organ in systemic carcinogenesis is the liver [146-148]. As expected, mutagenic effects were detected in the liver of the Muta™mouse, but none in the bone marrow [104,106,149,150]. The same mice showed also no micronuclei at these dose levels [104]. Consequently, the mouse bone marrow micronucleus test gave negative results indicating that this is not a target organ of genotoxicity. However, there is also evidence that this substance shows more gene mutagenic activity than clastogenic activity because other in vivo studies gave no clear indication for chromosome aberration (see Additional file 1).

N-Nitrosodi-N-propylamine
There is evidence that this substance shows more gene than chromosome mutagenic activity. Beside local carcinogenic effects in carcinogenicity studies on mice and rats systemic effects were located in the liver (mouse and rats) and in bone marrow (rat) [160-163]. Several target organs were detected in the Muta™mouse assay including liver and bone marrow [164]. But no chromosome mutagenic activity was recorded in the mouse bone marrow micronucleus test [4]. Further in vivo data on this endpoint are not available (see Additional file 1).

Phenobarbital
Liver tumours were detected in carcinogenicity studies on mice and rats [165-167]. In the Muta™mouse assay no mutagenic activity was observed although the liver weight of the treated mice increased indicating systemic effects in this organ [149,168]. Two studies are available on the Big Blue™ mouse, one gave negative [16] and the other weak positive results [169]. Taken together the results in transgenic mice are inconclusive which is in accord with the mouse bone marrow nucleus test (inconclusive results). Inconclusive (in vitro) or negative results were obtained in other studies on clastogenicity or other endpoints of genotoxicity (see Additional file 1).
Overall, there is no clear indication of gene or chromosome mutagenic activity in transgenic mouse assays or other genotoxic tests systems. However, genotoxic mechanisms in carcinogenicity cannot be excluded.

β-Propiolactone
This is an alkylating substance with predominantly local carcinogenic effects[175,176]. In the Muta™mouse assay [131] local effects in the stomach were observed in gavage studies plus systemic effects in the liver, but no mutagenic activity was seen in bone marrow of the Muta™mouse [131]. As expected, no increased incidence in micronuclei was detected in the bone marrow of treated mice [1,4] although clastogenic effects were observed in in vitro studies, in insects and plants (see Additional file 1) indicating chromosomal aberration after direct contact with this alkylating substance.

Trichloroethylene
This substance gave clearly positive results in different carcinogenicity studies on mice [186]. Although the target organs of carcinogenicity (including bone marrow) were investigated in the Muta™mouse assay, no mutagenic activity was noted [187]. The positive results in the mouse bone marrow micronucleus test are contradictory to other in vivo studies on clastogenicity. However, a further (simple) reason for the negative results in the Muta™mouse assay might be that the MTD was not reached [187]. Overall, further discussion on the mechanisms of carcinogenicity is necessary.

Tris(2,3-dibromopropyl)phosphate
This might be a further example for a substance where genotoxic effects are not related to the target organ bone marrow but induce systemic effects in others. The target organ in oral carcinogenicity studies on mice and rats was the kidney, in mice systemic carcinogenic effects were also seen in lung and liver [188-190]. In the Big Blue® mouse assay, mutagenic activity was detected in the kidney in gavage studies[46,191]. The mouse bone marrow micronucleus assay (i.p. injection)[4] as well as cytogenetic studies on rats and mice were negative [188-190].

Substances without carcinogenic effects in mice and differing results in the micronucleus test and transgenic mouse assay
4-Acetilaminofluorene
This substance showed mutagenic activity in the Muta™mouse assay [18] but inconclusive results in the mouse bone marrow micronucleus test [2]. No data on carcinogenicity are available on 4-acetilaminofluorene. However, data on two in vitro mammalian test systems indicated gene mutagenic activity [17] supporting results in the transgenic assay.

Substances with carcinogenic effects in mice but nongenotoxic mechanisms are presumed
Chloroform (German MAK Classification 4 = substances with carcinogen effects where the genotoxic effects are absent or only play an insignificant role)
Liver tumours were induced in B6C3F1 mice [72], however no mutagenic effects were detected in the liver of Big Blue® mice of the same strain in a valid assay [74]. Accordingly, no increased incidence in micronuclei were observed in the bone marrow of mice [1,47] and no clastogenicity in in vitro studies (see Additional file 1). In contrast, rats showed clastogenic activity in the kidney, but only at toxic dose levels [73].

Di-(2-ethylhexyl)phthalate (German MAK Classification 4)
This substance induced liver tumours in mice and rats [86]. No increased mutation frequency was seen in the liver of the Big Blue® mouse [16] (limited validity, MTD presumably not reached) and no chromosome aberration in the mouse micronucleus test [4]. The majority of in vitro and in vivo tests revealed also negative results with di-(2-ethylhexyl)phthalate (see Additional file 1).

Tetrachloromethane (German MAK Classification 4)
An increased incidence of liver tumours were induced in mice and in rats [185]. However, no mutagenic activity in the liver was reported in a Muta™mouse assay although the organ weight increased in the same mice indicating some hepatocellular regeneration [168]. No chromosome
aberration was induced in the mouse bone marrow micronucleus test [4]. Also other studies on this endpoint and the majority studies on other endpoint of genotoxicity revealed negative results (see Additional file 1).

**Discussion on the comparison of both assays**

Most carcinogens in Additional file 1 are positive in transgenic mouse assays and in the mouse bone marrow micronucleus test although different endpoints are studied. This indicates coincidence in both test systems and/or effects of the test substance on different genotoxic endpoints.

However, there are several substances (see above for example ortho-anisidine) whose mutagenic (and carcinogenic) potential could not be demonstrated with the mouse bone marrow micronucleus test but with the transgenic mouse assay. This might be due to the fact that the micronucleus test is restricted to the bone marrow as target organ. In contrast, all organs can be examined in transgenic mouse assay for mutagenic activity without any restrictions.

A special subgroup of substances should also be mentioned: substances with predominantly local mutagenic/carcinogenic effects and less systemic direction of effects. For these substances the mouse bone marrow micronucleus test is an unsuitable test system.

Beside the restrictions on the target organ there is also given the possibility that a substance induces predominantly gene mutations and not or less chromosome aberrations at the same dose level. The example N-nitrosodini-N-propylamine has shown positive results in different target organs including the bone marrow using the transgenic mouse assay but negative results were shown in the mouse micronucleus test.

On the other hand there are also substances for which the transgenic mouse assay is an unsuitable test system. The examples methylmethanesulfonate and mitomycin C have shown that chromosome aberration and not gene mutation is the predominant endpoint at the corresponding dose level in vivo. These genotoxic effects are not easily detectable with the transgenic mouse assay which is restricted to the detection of small deletion and insertions in the DNA. However, the negative Muta™mouse assay on mitomycin C has some limitations in the validity of the test system. With increased dose levels (MTD reached) and/or repeated application also gene mutagenic effects might be detected in the transgenic mouse assay.

Interestingly, substances with carcinogenic effects induced by nongenotoxic mechanisms gave mainly correct negative results in both test systems although the protocols for the transgenic mouse assays were not optimised except for chloroform.

**Predictability of the transgenic animal assays and the mouse bone marrow micronucleus test for carcinogenicity**

The sensitivity, specificity and predictive values to cancer for the Muta™mouse assay and the Big Blue® mouse assay combined, and the mouse bone marrow micronucleus test are documented in Table 1. In the present study data on 38 substances were available concerning carcinogenicity in mice and mutagenic effects in transgenic mice as well as mutagenic effects in the mouse bone marrow micronucleus test (Additional file 1). The two substances with inconclusive results in the mouse bone marrow micronucleus assay (phenobarbital & acrylamide) were not included in the final calculation data and in the combi-

### Table 1: Characteristics of the Muta™mouse assay and the Big Blue® mouse assay for predicting mouse carcinogenicity in comparison with the micronucleus test

| Term# | Calculation for the mouse bone marrow micronucleus test | Calculation for Muta™mouse and/or Big Blue® mouse combined * |
|-------|---------------------------------------------------------|-------------------------------------------------------------|
| Sensitivity | 68% (23/34) | 82% (28/34) |
| Specificity | 0% (0/2) | 100% (2/2) |
| Positive predictability | 92% (23/25) | 100% (28/28) |
| Negative predictability | 0% (0/11) | 25% (2/8) |
| Overall accuracy | 64% (23/36) | 83% (30/36) |

# Sensitivity = % of carcinogens with a positive result in the specified test system (STS)
Specificity = % of noncarcinogens with a negative result in STS
Positive predictability = % of positive results in the STS that are carcinogen
Negative predictability = % of negative results in the STS that are noncarcinogens
Overall accuracy = % of chemicals tested where STS results agree with the carcinogenicity results
Carcinogens with genotoxic and nongenotoxic mechanisms were considered but not noncarcinogenic substances; only data on mice were used
Weak positive results in transgenic mouse assays judged as positive.

*: judged as positive in transgenic assays if positive in one of the two test systems
parison of the micronucleus test versus the transgenic mouse assay.

Although the data pool in this document is not sufficient for a comprehensive comparison (low number of examples, especially for specificity and negative predictability; limitations of most transgenic mouse assays with negative results) some differences were apparent between the two test systems.

The overall accuracy of the micronucleus test is lower than that of the transgenic mouse assays. This is mainly due to 11 negative results in the micronucleus test system (negative in the micronucleus test but positive in carcinogenicity studies) influencing the terms sensitivity and negative predictability. Three of these negative results in the micronucleus test are obtained with carcinogenic substances [chloroform, di-(2-ethylhexyl)phthalate, and tetrachloromerthene] for which carcinogenic effects are considered to be of a non-genotoxic mechanism. However, chloroform, di-(2-ethylhexyl)phthalate and tetrachloromerthene gave negative results in transgenic mice, so the comparison of both test systems is not essentially affected and the evaluation "non-genotoxic" supported. For the other 8 substances out of these 11 with false negative results in the micronucleus test these results are explainable (see above): Ortho-anisidine (mutagenic/carcinogenic effects are restricted to the bladder), IQ (bone marrow presumably not target organ of genotoxicity in mice and more gene mutagenic than clastogenic), asbestos (local genotoxic/carcinogenic effects in the lung), 2,4-diaminotoluene (target organ liver, presumably not bone marrow), N-nitrosodiethylamine (target organ liver, more gene mutagenic than clastogenic), N-nitroso-N-propylamine (presumably more gene mutagenic than clastogenic), beta-propiolactone (mainly local effects and less systemic effects [in bone marrowl]), tris(2,3-dibromopropyl)phosphate (systemic effects not related to the bone marrow).

The term negative predictability is also low in the transgenic mouse assay due to false negative results on six carcinogenic substances; for three of them, hydrazine, mitomycin C, and tetrachloroethylene (detailed treatise in section "direct comparison", see above) genotoxic mechanisms are presumed. For hydrazine (no repeated application) and tetrachloroethylene (MTD not reached) limitations on the experimental design might be the reason for the negative results. Mitomycin C is clearly more clastogenic than gene mutagenic, and the transgenic mouse with lacI and lacZ is possibly an unsuitable test system. For 3 out of the 6 substances the carcinogenic effects in mice were attributed to nongenotoxic mechanisms: chloroform, di-(2-ethylhexyl)phthalate and tetrachloromerthene (see also above), all gave negative results in transgenic mice.

Only two substances with negative results in long-term carcinogenicity studies are available in the data pool: bromomethane and 2,6-diaminotoluene. Both gave correct negative results in the transgenic mouse assay (although of limited validity) but false positive results in the micronucleus test (see term specificity).

Generally, the differences between the two test systems might be due to the fact that 1) unequal genotoxic endpoints are investigated (chromosome aberration in the micronucleus test versus gene mutation in the transgenic mouse assay), 2) organotrophy of genotoxic effects (especially bone marrow not target organ) might play an essential role and 3) transgenic rodent assay conditions in the different systems may not be optimal for mutation detection.

**Advantages and disadvantages of both test systems**

A comparison of the transgenic mouse assays with the mouse bone marrow micronucleus test is limited by the fact that different genotoxic endpoints are studied in these two systems. In transgenic mouse assays, point mutations and small insertions and deletions are detected whereas in the mouse bone marrow assay, chromosome breakage leading to light microscopically visible micronuclei resulting from chromosome fragment or micronuclei originating from whole chromosomes are investigated.

**Sensitivity of the test system**

In comparison to other test systems in genotoxicity testing using endogenous target structures the spontaneous mutant frequency in the transgenic mouse assay is relatively high. This might be related to the fact that bacterial DNA is the target gene (high methylation rate) or the transgene is silent and no transcription related repair occurs like in endogenous genes which are more efficiently repaired [9]. In the mouse bone marrow micronucleus test the spontaneous rate of micronuclei is low ranging between 1–3 PCEs with micronuclei per 1000 PCEs. However, frequency of chromosome aberrations is not directly comparable with a gene mutation frequency.

Comparing the target organs and cells at risk at the time of exposure, the mouse micronucleus test is restricted to one target organ, the bone marrow, especially to the erythroblasts. This limitation is not given in transgenic mouse assays: target cells are cells in all organs [195].

**Considerations of animal welfare**

Both test systems are similar in the number of animals used for a valid test. The minimal number of mice needed in the mouse bone marrow assay is 25 per gender (3 dose levels, vehicle control, positive control; 5 mice per group) using a treatment schedule with 2 or more applications at 24 h intervals and sampling 18–24 h following the final
In the limit test (for a test substance of low toxicity) only one dose level of 2000 mg/kg bw is necessary (OECD guideline 474, [6]).

In transgenic mutation assays ca. 20 animals (3 dose groups and 1 concurrent vehicle control group in laboratories which already established this test system) are recommended per species and gender [196,197]. In terms of animal welfare, it is also desired to merge more than one in vivo genotoxicity assay such as transgenic mouse assay and micronucleus assay using the same animals for both assays.

### Table 2: Comparison of the mouse bone micronucleus assay with transgenic mouse models (Muta™ mouse and the Big Blue® assay)

| Type of endpoint                | Mouse bone marrow micronucleus test [1,2]                                                                 | Transgenic mouse mutation assay [9,195]                                                                 |
|--------------------------------|------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| **Type of endpoint**           | Detects light microscopically visible micronuclei resulting from whole chromosomes or chromosome fragments following chromosome breakage | Detects 1) gene mutation, 2) small deletions or insertions                                               |
| **Regulatory use**             | Widespread acceptance (OECD guideline established since 1983)                                             | Not widely used by the industry in toxicological screening; OECD guideline in preparation                |
| **Background mutation rate**   | Spontaneous incidence of micronuclei is low (ca. 0.3%) and almost uniform                                | High spontaneous rate of mutations comparing with other mutation assays                                   |
| **Negative predictivity**      | Low negative predictivity for cancer                                                                      | Low negative predictivity for cancer                                                                      |
| **Implementation**             | Simplicity of the test system; easily recognised end-point                                                | Higher Complexity of the test system (target cells in mice and expression of mutagenic effects in bacteria; vector system needed) |
| **Toxicokinetics and metabolism** | Restrictions in toxicokinetics: test substance or the toxic metabolites may not reach the bone marrow but other target organs | No restrictions after absorption and distribution of the test substance                                  |
| **Target tissue**              | Restricted to erythroblasts in the bone marrow                                                            | No tissue restriction; analysis of mutagenic potency in different organs; measurement of organotrophic effects |
| **Dependency of effects on application route** | Only systemic effects can be detected                                                                     | Systemic as well as local mutagenic effects can be detected                                             |
| **Number of animals**          | 5 animals per gender per dose recommended                                                                 | 5 animals per gender per dose recommended                                                                |
| **Restrictions on the used model** | Also some recommendations are given in OECD guideline 474, no limitation concerning species, strain, gender, age of animals, exposure duration | Limitations: Muta™ mouse assay only 1 species & 1 strain; Big Blue® 2 species (mouse and rat) but 1 (rat) or 2 strains (mouse); no limitations on other parameters |
| **Costs**                      | Less expensive due to the simplicity of the test system                                                   | More expensive test system                                                                               |
| **Molecular mechanism**        | Mechanisms of the induction of micronuclei originating from chromosome fragments could not be resolved   | Detection of the "molecular signature" of a particular mutagenic substance by DNA sequence analysis with standardised methods |
| **Parallel examination of different genetic endpoints** | Combination with other genotoxic endpoints is not recommended but possible if results of the micronucleus test are not influenced and vice versa | The transgenic mouse assay can be combined with other in vivo genotoxic endpoints in the same animal: micronuclei, chromosomal aberration, UDS, SCE |
| **Type of mutational target**  | In situ end point                                                                                        | Target genes are integrated parts of foreign DNA and consequently no "normal" mutational target, no expression |

UDS: unscheduled DNA synthesis; SCE: sister chromatid exchange.

**Cost effectiveness**

Due to the simplicity of the mouse bone marrow micronucleus assay and the use of systems for automated analysis, this test is less expensive than the transgenic mouse assay.

A comparison both test systems is presented in Table 2.

**Conclusions**

In a comparison of the tests available to genetic toxicologists, the results from studies on substances which had been tested in transgenic mutagenicity assays Big Blue® mouse and the Muta™ mouse were compared with those from the more traditional mouse bone marrow micronucleus test. The transgenic animal mutation assay, which is
not yet used in toxicological screening, is not directly comparable with the micronucleus test, because different genetic endpoints are examined: chromosome aberration versus gene mutation. However, from the 39 substances, the majority gave the same positive or negative result in both test systems. The substances where differences occurred were discussed in more detail. The advantages and disadvantages of the transgenic Big Blue® mouse and the Muta™Mouse transgenic model compared to the micronucleus test were discussed and both systems were found to have a place in mutagenicity testing and to supplement each other. The transgenic animal assay has, however, some distinct advantages over the micronucleus test in that it is not restricted to one target organ and detects systemic as well as local mutagenic effects.

Authors' contributions
UW was the main author. The other authors were involved in the discussions, writing small parts of text and in final preparation of the manuscript.

Additional material

Additional File 1
Table: Results in the transgenic mouse assay versus mouse bone marrow micronucleus test
Click here for file [http://www.biomedcentral.com/content/extra/1477-3163-4-3-S1.doc]

Acknowledgements
This paper is based on work performed by the authors in preparation of an Environmental Health Criteria document on Transgenic Animals in Mutagenicity Testing for the International Programme on Chemical Safety (IPCS). However, opinions expressed in this paper are the sole responsibility of the authors. We acknowledge the financial support of the German Federal Ministry for the Environment, Nature Conservation and Nuclear Safety.

References
1. Heddle JA, Hite M, Kirkhart B, Mavournin K, MacGregor JT, Newell GW, Salamone MF: The induction of micronuclei as a measure of genotoxicity: A report of the U.S. Environmental Protection Agency gene-tox program. Mutat Res 1983, 123:61-118.
2. Mavournin KH, Blakely DH, Cimino MC, Salamone MF, Heddle JA: The in vivo micronucleus assay in mammalian bone marrow and peripheral blood. A report of the U.S. Environmental Protection Agency gene-tox program. Mutat Res 1990, 239:29-80.
3. Shelby MD, Erexson GL, Hook GJ, Tice RR: Evaluation of a three-exposure mouse bone marrow micronucleus protocol: results with 49 chemicals. Environ Mol Mutagen 1993, 21:160-179.
4. Morita T, Asano N, Awogi T, Sasaki Y, Sato S, Shimada H, Sotou S, Suzuki T, Wakata A, Sofuni T, Hayashi M: Evaluation of the rodent micronucleus assay in the screening of IARC carcinogens (groups 1, 2A and 2B). The summary report of the 6th collaborative study by CSGMT/JEMS MMS. (Collaborative study of the micronucleus group test mammalian mutagenicity study group). Mutat Res 1997, 389:3-122.
5. Morita T, Asano N, Awogi T, Sasaki Y, Sato S, Shimada H, Sotou S, Suzuki T, Wakata A, Sofuni T, Hayashi M: Erratum to "Evaluation of the rodent micronucleus assay in the screening of IARC carcinogens (groups 1, 2A and 2B). The summary report of the 6th collaborative study by CSGMT/JEMS MMS". Mutat Res 1997, 391:259-267.
6. OECD: OECD 474: mammalian erythrocyte micronucleus test; OECD guideline for the testing of chemicals 1997.
7. Kohler SW, Provost GS, Fleck A, Kretz PL, Bullock WO, Putman DL, Sorge JA, Short JM: Analysis of spontaneous and induced mutations in transgenic mice using a lambda ZAP/lacI shuttle vector. Environ Mol Mutagen 1991, 18:316-321.
8. Gossen JA, De Leeuw WV, Tan CHT, Zwarthoff EC, Berends F, Lohman PHM, Knoop DL, Vijg J: Efficient rescue of integrated shuttle vectors from transgenic mice: a model for studying mutations in vivo. Proc Natl Acad Sci U S A 1989, 86:7991-7995.
9. RIWM: Mutagenicity of chemicals in genetically modified animals. RIWM Report no. 650210 002, TNO Report no. 199.1097 Bilthoven: National Institute of Public Health and the Environment (RIWMM); 2000.
10. Gossen J, Vijg J: Transgenic mice as model systems for studying gene mutations in vivo. Trends Genet 1993, 9:27-31.
11. Shephard SE, Sengstac C, Lutz WK, Schlatter M: Mutations in liver DNA of transgenic mice following subchronic exposure to 2-acetylaminofluorene. Mutat Res 1993, 302:91-96.
12. Hazardous Substances Data Bank (HSDB) 2-Acetylaminofluorene, Factsheet CAS: 53-96-3 [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?HSDB]
13. National toxicology program (NTP) 2-Acetylaminofluorene, Factsheet CAS: 53-96-3 [http://ntp-server.niehs.nih.gov/]
14. Brooks TM, Szegedi M, Roscher P, Dean SW: The detection of gene mutation in transgenic mice (Muta Mouse) following a single oral dose of 2-acetylaminofluorene. Mutagenesis 1995, 10:149-150.
15. Ross JA, Leavitt SA: Induction of mutations by 2-acetylaminofluorene in lac transgenic B6CF1 mouse liver. Mutagenesis 1998, 13:173-179.
16. Gunz D, Shephard SE, Lutz WK: Can nongenotoxic carcinogens be detected with the lac transgenic mouse mutation assay? Environ Mol Mutagen 1993, 21:209-211.
17. Genetic Toxicology (GENETOX) 4-Acetylaminofluorene, CAS: 28322-02-3 [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?GENETOX]
18. Tinwell H, Lefevre PA, Ashby J: Relative activities of methyl methanesulphonate (MMS) as a genotoxin, clastogen and gene mutagen to the liver and bone marrow of Muta mice. Environ Mol Mutagen 1998, 32:163-172.
19. IARC: Acrylamide. In Some naturally occurring substances; food items and contaminants, heterocyclic aromatic amines and mycotoxins. Monographs on the evaluation of carcinogenic risks to humans, No. 60 Lyon: International Agency for Research on Cancer (IARC); 1994:389-433.
20. Chemical Carcinogenesis Research Info System (CCRIS) 1996, Acrylamide, CAS: 79-06-1 [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?CCRIS]
21. Myhr B: Validation studies with Muta mouse: a transgenic mouse model for detecting mutations in vivo. Environ Mol Mutagen 1991, 18:308-315.
22. Hoon AJW, Custer LL, Myhr BC, Brusick D, Gossen J, Vijg J: Detection of chemical mutagens using Muta Mouse: a transgenic mouse model. Mutagenesis 1993, 8:7-10.
23. Krebs O, Favor J: Somatic and germ cell mutagenesis in lambda lacZ transgenic mice treated with acrylamide or ethlynitosourea. Mutat Res 1997, 388:239-248.
24. IARC: Acrylamide. In Some naturally occurring substances; food items and constituents, heterocyclic aromatic amines and mycotoxins. Monographs on the evaluation of carcinogenic risks to humans, No. 56 Lyon: International Agency for Research on Cancer (IARC); 1993:245-395.
25. Aaturup H, Jorgensen ECB, Jensen O: Aflatoxin B1 induced lacZ mutation in liver and kidney of transgenic mice c57BL/6N: effect of phorone. Mutagenesis 1996, 11:69-73.
26. Davies R, Orello VIC, Martin EA, Festing MFW, White INH, Smith LL, Styles JA: Tamoxifen causes gene mutations in the livers of lambda/lacZ transgenic mice. Cancer Res 1997, 57:1288-1293.
27. Dycalo MJ, Stuart GR, Tobal GM, de Boer JG, Glickman BW, Provost GS: Species-specific differences in hepatic mutant frequency and mutational spectrum among lambda/lacZ transgenic rats and mice following exposure to aflatoxin B1. Carcinogenesis 1996, 17:2347-2356.

Journal of Carcinogenesis 2005, 4:3 http://www.carcinogenesis.com/content/4/1/3

(page number not for citation purposes)
28. Trzos RJ, Petzold GL, BRANDEN MN, SWENBERG JA: The evaluation of sixteen carcinogens in the rat using the micronucleus test. Mutat Res 1995, 357:79-86.

29. IARC: 4-Aminobiphenyl. In Some inorganic substances, chlorinated hydrocarbons, aromatic amines, N-nitroso compounds, and natural products. Monographs on the evaluation of the carcinogenic risk of chemicals to man. No. 1 Lyon: International Agency for Research on Cancer (IARC); 1971:74-79.

30. Genetic Toxicology (GENETOX) 4-Amino-1,1'-biphenyl, CAS: 92-67-1 [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?GENETOX]

31. Chemical Carcinogenesis Research Info System (CCRIS) 4-Aminobiphenyl, CAS: 92-67-1 [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?CCRIS]

32. Fletcher K, Tinwell H, Ashby J: Mutagenicity of the human bladder carcinogen 4-aminobiphenyl to the bladder of Muta Mouse transgenic mice. Mutat Res 1998, 400:245-250.

33. IARC: 1,3-bis(2-chloroethyl)-1-nitrosourea. In Some naturally occuring substances; food items and constituents, heterocyclic amines and mycotoxins. Monographs on the evaluation on carcinogenic risks to humans, No. 56 Lyon: International Agency for Research on Cancer (IARC); 1993:165-195.

34. IARC: 4-aminobiphenyl, CAS: 92-67-1 [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?IRIS]

35. Wild D, Gocke E, Harmsch D, Kaiser G, King MT: Differential mutagenic activity of IQ (2-amino-3-methylimidazo(4,5-F)quinoline) in Salomonena typhimurium strains in vitro and in vivo, in Drosophila, and in mice. Mutat Res 1985, 156:93-102.

36. European Chemicals Bureau: European Union Risk Assessment Report, o-anisidine Luxembourg: Office for Official Publications of the European Communities; 2009.

37. Ashby J, Short JM, Jones ND, leFeuvre PA, Provost GS, Rogers BJ, Martin EA, Parry JM, Burnette K, Glickman BW, Tinwell H: Mutagenicity of o-anisidine to the bladder of lacI-transgenic B6C3F1 mice: absence of 14C or 32P bladder DNA adduction. Carcinogenesis 1994, 15:2291-2296.

38. IARC: Asbestos (Group 1). In Overall evaluations of carcinogenicity: an updating of IARC Monographs Volume 1 to 42. Monographs on the evaluation of carcinogenic risks to humans, Suppl. 7 Lyon: International Agency for Research on Cancer (IARC); 1987:106-116.

39. IARC: Asbestos. In Genetic and related effects: an updating of selected IARC monographs from volumes 1 to 42. Monographs on the evaluation of carcinogenic risks to humans, Suppl. 6 Lyon: International Agency for Research on Cancer (IARC); 1987:77-80.

40. IARC: Asbestos. Monographs on the evaluation of carcinogenic risk of chemicals to man. No. 14 Lyon: International Agency for Research on Cancer (IARC); 1977:1-106.

41. Rihm B, Coulais C, Kauffer E, Bottin M-C, Martin P, Yvon F, Vigneron JC, Binet S, Monhoven N, Stebilen G, Keith G: Inhaled crocidolite mutagenicity in lung DNA. Environ Health Perspect 2000, 108:341-346.

42. IARC: Benzene. In Some industrial chemicals and dyestuffs. Monographs on the evaluation of the carcinogenic risk of chemicals to humans, No. 29 Lyon: International Agency for Research on Cancer (IARC); 1982:94-148.

43. WHO: Benzene. International Programme on Chemical Safety, Environmental Health Criteria 150 Geneva: World Health Organization; 1993.

44. Provost GS, Mirsalis [C, Rogers B]. Short JM: Mutagenic response to benzo[a]pyrene with mouse and rat peripheral blood reticulocytes. Mutat Res 1992, 278:165-168.

45. WHO: Selected Non-heterocyclic Polyyclic Aromatic Hydrocarbons. International Programme on Chemical Safety, Environmental Health Criteria 202 Geneva: World Health Organisation; 1998.

46. Skopek TR, Kort KL, Marino DR, Mital LV, Umbehauer DR, Laws GP, Adams SP: Mutagenic response of the endogenous hprt gene and lac transgene in benzo[a]pyrene-treated Big Blue B6C3F1 mice. Environ Mol Mutagen 1996, 28:376-384.

47. Pletsch V, Steenwinkel MJ, van Delft JH, Loehman PBM, Haan RA: Comparison of the X-gal- and X-gal-based systems for screening of mutant #lambda#lacZ phages originating from the transgenic mouse strain 40.6. Mutat Res 1996, 360:101-106.

48. Kornberg S, Tsutsui Y, Sonoda J, Mikami T, Tsukidate K, Sagiomi F, Kerns WD: Multiple organ mutation in the lacZ transgenic mouse (Muta Mouse) 6 months after oral treatment (5 days) with benzo[a]pyrene. Mutat Res 1999, 426:71-77.

49. Kohler SW, Provost GS, Fieck A, Kretz PL, Bullock WO, Sorge J, Putman DL, Short JM: Spectra of spontaneous and mutagen-induced mutations in the lac gene in transgenic mice. Proc Natl Acad Sci USA 1991, 88:7958-7962.

50. Skopek TR, Kort KL, Marino DR, Mital LV, Umbehauer DR, Laws GP, Adams SP: Mutagenic response of the endogenous hprt gene and lac transgene in benzo[a]pyrene-treated Big Blue B6C3F1 mice. Environ Mol Mutagen 1996, 28:376-384.

51. Pletsch V, Steenwinkel MJ, van delft JH, Baan RA, Kyrtopoulos SA: Methyl bromide causes DNA methylation in rats and mice but fails to induce somatic mutations in lambda lacZ transgenic mice. Cancer Lett 1995, 135:217-227.

52. Araki A, Tsutsui Y, Sonoda J, Mikami T, Tsukidate K, Sagiomi F, Kerns WD: Multiple organ mutation in the lacZ transgenic mouse (Muta Mouse) 6 months after oral treatment (5 days) with benzo[a]pyrene. Mutat Res 1999, 426:71-77.

53. Recio L, Bond JA, Pluta LJ, Sisk SC: Use of transgenic mice for assessing the mutagenicity of 1,3-butadiene in vivo. IARC (Int Agency Res Cancer) Sci Pub 1993, 127:235-243.

54. Sisk SC, Pluta LJ, Bond JA, Recio L: Molecular analysis of lac mutants from bone marrow of B6C3F1 transgenic mice following inhalation exposure to 1,3-butadiene. Carcinogenesis 1994, 15:471-477.

55. Recco L, Meyer KG, Pluta LJ, Moss OR, Saranko CJ: Assessment of 1,3-butadiene mutagenicity in the bone marrow of B6C3F1 lac transgenic mice (Big Blue): a review of mutagenic spectrum and lac mutant frequency after a 5-day 625 ppm 1,3-butadiene exposure. Environ Mol Mutagen 1996, 28:424-429.

56. Environ Mol Mutagen 1996, 28:424-429.

57. Cunningham MJ, Choy WN, Arce GT, Rickard LB, Vlachos DA, Kinyary LA, Sarrif AM: In vivo sister chromatid exchange and micronucleus induction studies with 1,3-butadiene in B6C3F1 mice and Sprague-Dawley rats. Mutagenesis 1986, 1:449-452.

58. IARC: Chlorambucil. In Some antineoplastic and immunosuppressive agents. Monographs on the evaluation of the carcinogenic risk chemicals to humans, No. 26 Lyon: International Agency for Research on Cancer (IARC); 1981:115-136.

59. IARC: Chlorambucil (Group 1). In Overall evaluations of carcinogenicity: an updating of IARC Monographs Volumes 1 to 42. Monographs
on the evaluation of carcinogenic risks to humans, Suppl. 7 Lyon: International Agency for Research on Cancer (IARC); 1987:144-145.

69. Genetic Toxicology (GENETOX) Chlorambucil, CAS: 105-03-3 [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?GENETOX]

70. Chemical Carcinogenesis Research Info System (CCRIS) Chlorambucil, CAS: 105-03-3 [http://toxnet.nlm.nih.gov/cgi-bin/cr/criss/htmlgen/CCRIS]

71. Hazardous Substances Data Bank (HSDB) Chlorambucil, CAS: 105-03-3 [http://toxnet.nlm.nih.gov/cgi-bin/cr/criss/htmlgen/HSDB]

72. DFG. Chloroform. In Occupational toxicants – critical data evaluation for MAK values and classification of carcinogens, Volume 14. Deutsche Forschungsgemeinschaft (DFG) Weinheim: Wiley-VCH; 2000:19-58.

Robbiani L, Mereto E, Morando AM, Pastore P, Brambilla G. Increased frequency of micronucleated kidney cells in rats exposed to halogenated anaesthetics. Mutat Res 1998, 413:1-6.

Butterworth BE, Templin MV, Constan AA, Sprankle CS, Wong BA, Hayward JJ, Recio L. Long-term mutagenicity studies with chloroform and dimethylnitrosamine in female lactating B6C3F1 mice. Environ Mol Mutagen 1998, 31:248-256.

73. IARC. Cyclophosphamide. In Some antineoplastic and immunosuppressive agents. Monographs on the evaluation of the carcinogenic risk of chemicals to humans, No. 26 Lyon: International Agency for Research on Cancer (IARC); 1981:165-202.

74. IARC. Cyclophosphamide (Group 1). In Overall evaluations of carcinogenicity: An updating of IARC Monographs volumes 1 to 42. Monographs on the evaluation of carcinogenic risks to humans, Suppl. 7 Lyon: International Agency for Research on Cancer (IARC); 1987:182-184.

75. Gorelick NJ, Andrews JL, Gu M, Glickman BW. Tissue-specific mutant frequencies and mutational spectra in lact gene in skin from 7,12-dimethylbenzaanthracene-treated and untreated transgenic mice. Mol Carcinogen 1995, 167-181.

Machemer LJ, Lorko D. Mutagenicity studies with praziquantel, a new anthelmintic drug, in mammalian systems. Arch Toxicol 1978, 39:187-197.

80. Cunningham ML, Hayward JJ, Shore BS, Tindall KR. Distinction of mutagenic carcinogens from a mutagenic noncarcinogen in the Big Blue transgenic mouse. Environ Health Perspect 1996, 104:683-686.

81. Sisk SC, Pluta LJ, Meyer KG, Wong BC, Recio L. Assessment of the in vivo mutagenicity of ethylene oxide in the tissues of B6C3F1 lac transgenic mice following inhalation exposure. Mutat Res 1997, 391:153-164.

82. Sisk SC, Pluta LJ, Meyer KG, Wong BC, Recio L. In vivo mutagenicity of ethylene oxide at the hprt locus in T-lymphocytes of B6C3F1 lac transgenic mice following inhalation exposure. Mutat Res 1997, 392:211-222.

83. Jermyn DC, Ravel C. The micronucleus test as part of a short-term mutagenicity test program for the prediction of carcinogenicity evaluated by 143 agents tested. Mutat Res 1980, 75:191-202.

84. IARC. Ethyl methanesulfonate. In Some anti-thyroid and related substances, nitrofurans and industrial chemicals. Monographs on the evaluation of the carcinogenic risk of chemicals to man, No. 7 Lyon: International Agency for Research on Cancer (IARC); 1974:245-251.

85. Dutch expert committee for occupational standards (DECOS): Health-based recommended occupational exposure limits for ethyl methanesulfonate (EMS) and methyl methanesulfonate (MMS) Voorburg: Directorate-General of Labour, RA 4/89, 1989.

86. Chemical Carcinogenesis Research Info System (CCRIS) Ethyl methanesulfonate, CAS: 62-50-0 [http://toxnet.nlm.nih.gov/cgi-bin/cr/criss/htmlgen/CCRIS]

87. Genetic Toxicology (GENETOX) Ethyl methanesulfonate, CAS: 62-50-0 [http://toxnet.nlm.nih.gov/cgi-bin/cr/criss/htmlgen/GENETOX]

88. Hachiya N, Yajima N, Hatakeyama S, Yunoki K, Okada N, Umeda Y, Wakata A, Motohashi Y. Induction of lacZ mutation by 7,12-dimethylbenz[a]anthracene in various tissues of transgenic mice. Mutat Res 1999, 444:283-295.

89. Suzuki T, Ishii S, Nakajima M, Hashiya N, Hara T. Target organ and time-course in the mutagenicity of five carcinogens in Muta Mouse: a summary report of the second collaborative study of the transgenic mouse mutation assay by the JEMS/MMS. Mutat Res 1999, 444:259-268.

90. Ashby J, Bruckdick D, Myhr BC, Jones NJ, Parry JM, Nesnow S, Paton D, Tinwell H, Rosenkrans HS, Curti S, Gilman D, Callander RD. Correlation of carcinogenic potency with mouse-skin 32P-postlabeling and Muta Mouse lacZ-mutation data for DMBA and its K-region sulphur isosteres: comparison with activities observed in standard genotoxicity assays. Mutat Res 1993, 292:25-40.

91. Ashby J, Bruckdick D, Myhr BC, Jones NJ, Parry JM, Nesnow S, Paton D, Tinwell H, Rosenkrans HS, Curti S, Gilman D, Callander RD. Correlation of carcinogenic potency with mouse-skin 32P-postlabeling and Muta Mouse lacZ-mutation data for DMBA and its K-region sulphur isosteres: comparison with activities observed in standard genotoxicity assays. Mutat Res 1993, 292:25-40.

92. Gorelick NJ, Andrews JL, Gu M, Glickman BW. Mutational spectra in the lac gene in skin from 7,12-dimethylbenzaanthracene-treated and untreated transgenic mice. Mol Carcinogen 1995, 167-181.
108. Genetic Toxicology (GENETOX) 1-Ethyl-1-nitrosourea, CAS: 759-73-9 [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?GENETOX]
109. JEMS/MMS: Organ variation in the mutagenicity of ethylnitrosourea in Muta Mouse: results of the collaborative study on the transgenic mutation assay by JEMS/MMS. Environ Mol Mutagen 1996, 28:363-375.
110. Douglas GR, Jiao J, Gingerich JD, Gossen JA, Soper LM: Temporal and molecular characteristics of mutations induced by ethylnitrosourea in germ cells isolated from seminiferous tubules and in spermatozoa of lacZ transgenic mice. Proc Natl Acad Sci USA 1995, 92:7485-7489.
111. Gorelick NJ, Andrews JL, Gibbons DP, Carr GJ, Aardema MJ: Evaluation of lactation mutation in germ cells and micronuclei in peripheral blood after treatment of male lact transgenic mice with ethylnitrosourea, isopropylmethyl sulfate or methylmethane sulfonate. Mutat Res 1997, 388:187-195.
112. Durr D, Young RR: Evaluation of spontaneous and chemical-induced lactation mutations in germ cells from lambda/lact transgenic mice. Mutat Res 1997, 388:137-143.
113. Winegar RA, Carr G, Mirasalis JC: Analysis of the mutagenic potential of ENU and MMS in germ cells of male C57BL/6 lacI transgenic mice. Mutat Res 1999, 438:175-180.
114. Katoh M, Horiya N, Valdivia RPA: Benz[a]pyrene in control and ENU-treated Big Blue mice. Environ Mol Mutagen 1995, 25:249-256.
115. Provost GS, Short JM: Characterization of mutations induced by ethylnitrosourea in seminiferous tubule germ cells of transgenic B6CF1 mice. Proc Natl Acad Sci USA 1994, 91:6564-6568.
116. Skopek TR, Kort KL, Marin DR: Relative sensitivity of the endogenous hpt gene and lacI transgene in ENU-treated Big Blue B6CF1 mice. Environ Mol Mutagen 1995, 26:9-15.
117. Shibuya T, Morimoto K: A review of the genotoxicity of 1-ethyl-1-nitrosourea. Mutat Res 1993, 297:3-38.
118. BUAX: Hydrazin, Hydrazinhydrat und Hydrazinsulfate. Beratungsgremium für umweltrelevante Alkohole. BUAX Stoffbericht 205 Stuttgart: S. Hirzel Verlag, 1995.
119. Douglas GR, Gingerich JD, Gossen JA, Soper LM: Detection of gene mutation in the tubular sperm of Muta™Mice following a single intraperitoneal treatment with methyl nitrosourea or ethylnitrosourea. Mutat Res 1997, 388:219-222.
120. Renault D, Brault D, Thybaud V: Effect of ethylnitrosourea and methyl methanesulfonate on mutation frequency in Muta™Mouse germ cells (seminiferous tubule cells and epididymis spermatozoa). Mutat Res 1997, 388:145-153.
121. IARC: Methyl methanesulfonate. In: Evaluation of some organic chemicals, hydrocarbons and halogenated hydrocarbons. Monographs on the evaluation of the carcinogenic risk to humans, No. 73, Lyon: International Agency for Research on Cancer (IARC); 1997:253-260.
122. Brooks TM, Dean SW: The detection of gene mutation in the tubular sperm of Muta™Mice following a single intraperitoneal treatment with methyl methanesulfonate or ethylnitrosourea. Mutat Res 1997, 388:219-222.
123. IARC: N-Methyl-N’-nitro-N-nitrosoguanidine. In: Genetic and related effects: an updating of selected IARC monographs from volumes 1 to 42. Monographs on the evaluation of carcinogenic risks to humans, Suppl. 6 Lyon: International Agency for Research on Cancer (IARC); 1987:394-398.
124. IARC: N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) (Group 2A). In: Overall evaluations of carcinogenicity: an updating of IARC Monographs Volumes 1 to 42. Monographs on the evaluation of carcinogenic risk to humans, Suppl. 7 Lyon: International Agency for Research on Cancer (IARC); 1987:248-250.
125. Braut D, Bouilly C, Renault D, Thybaud V: Tissue-specific induction of mutations by acute oral administration of N-methyl-N’-nitro-N-nitrosoguanidine and beta-galactosidase in the Muta Mouse: preliminary data on stomach, liver and bone marrow. Mutat Res 1996, 360:83-87.
126. Brooks TM, Dean SW: Detection of gene mutation in skin, stomach and liver of Muta Mouse following oral or topical treatment with N-methyl-N’-nitrosoguanidine or 1-chloromethylpyrene: some preliminary observations. Mutagenesis 1996, 11:529-532.
127. IARC: N-nitroso-N-methyleurea. In Some N-nitroso compounds. Monographs on the evaluation on carcinogenic risk of chemicals to humans, No. 17 Lyon: International Agency for Research on Cancer (IARC); 1978:227-255.
128. Genetic Toxicology (GENETOX) 1-Methyl-1-nitrosourea, CAS: 684-93-5 [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?GENETOX]
129. von Pressentin Mdm, Kosinska W, Guttenplan JB: Mutagenesis induced by oral carcinogens in lacZ mouse (Muta Mouse) tongue and other oral tissues. Carcinogenesis 1995, 20:2167-2170.
130. Monroe J, Kort KL, Miller JE, Marino DR, Skopek TR: A comparative study of in vivo mutation assays: analysis of hprt, lacI, cl/ cl and mutational targets for N-nitros-N-methyleurea and benzo[a]pyrene in Big Blue mice. Mutat Res 1998, 421:121-136.
131. Shepard SE, Gunz D, Schlatter C: Genotoxicity of agaricine in the lacI transgenic mutation mouse assay: evaluation of the health risk of mushroom consumption. Food Chem Toxicol 1995, 33:257-264.
132. Provost GS, Kretz P, Hamner RT, Matthews CD, Rogers BJ, Lundberg KS, Dycxico MJ, Short JM: Transgenic systems for in vivo muta- tion analysis. Mutat Res 1993, 288:133-149.
133. IARC: Mitomycin C. In: Some naturally occurring substances. Monographs on the evaluation of the carcinogenic risk of chemicals to man, No. 10 Lyon: International Agency for Research on Cancer (IARC); 1976:171-179.
134. Chemical Carcinogenesis Research Info System (CCRIS) Mitomycin C, CAS: 50-07-7 [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?CCRIS]
135. Genetic Toxicology (GENETOX) 1998, Mitomycin C, CAS: 50-07-7 [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?GENETOX]
136. Suzuki T, Hayashi M, Sofuni T, Myhr BC: The concomitant detection of gene mutation and micronucleus induction by mito- mycin C in vivo using lacI transgenic mice. Mutat Res 1993, 285:219-224.
137. Genetic Toxicology (GENETOX) 4-Nitroquinoline 1-Oxide, CAS: 56-57-5 [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?GENETOX]
138. Chemical carcinogenesis research information system (CCRIS) 4-Nitroquinoline 1-Oxide, CAS: 56-57-5 [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?CCRIS]
139. Nakajima M, Kukuchi M, Saeki K, Miyata Y, Terada M, Kishida F, Yamamoto R, Furuhata C, Dean SW: Mutagenicity of 4-nitroquinoline 1-oxide in the Muta Mouse. Mutat Res 1999, 444:321-336.
140. IARC: N-Nitrosodiethylamine. In Some N-nitro compounds. Monographs on the evaluation of the carcinogenic risk of chemicals to humans, No. 17 Lyon: International Agency for Research on Cancer (IARC); 1978:89-106.
141. Chemical Carcinogenesis Research Info System (CCRIS) N, N-Diethylnitrosamine, CAS: 55-18-5 [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?CCRIS]
142. Genetic Toxicology (GENETOX) Diethylnitrosamide, CAS: 55-18-5 [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?GENETOX]
143. Okada N, Honda A, Kawabata M, Yajima N: Sodium phenobarbi- tal-enhanced mutation frequency in the liver DNA of lacZ transgenic mice treated with diethylnitrosamide. Mutagenesis 1997, 12:179-184.

http://www.carcinogenesis.com/content/4/1/3

Page 12 of 14 (page number not for citation purposes)
150. Suzuki T, Hayashi M, Myhr B, Sofuni T: Diethylnitrosamine is mutagenic in liver but not in bone marrow of lacZ transgenic mice (Muta Mouse). Hongyo Dobutsu Shiken Bunkakai, Kairi 1995, 3:33-39.

151. IARC: N-nitrosodimethylamine. In Some N-nitroso compounds. Monographs on the evaluation of the carcinogenic risk of chemicals to humans, No. 17 Lyon: International Agency for Research on Cancer (IARC); 1978:125-175.

152. Genetic Toxicology (GENETOX) Dimethylnitrosamine, CAS: 62-75-9 [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?GENETOX]

153. Schmezer P, Eckert C, Liegibel U, Klein R, Bartsch H: Mutagenic structural modification of quinoline assessed by specific expression times in lacZ transgenic mice. Mutat Res 1999, 414:151-169.

154. Wang X, Suzuki T, Itoh T, Uno Y, Idehara K, Baba T, Maniwa J, Ohkouchi A, Wang X, Hayashi M, Sofuni T, Tsuruoka M, Miyajima H, Kondo K: Procarbazine genotoxicity in the Muta Mouse; strong clastogenicity and organ-specific induction of lacZ mutations. Mutat Res 1999, 444:269-281.

155. Pitzka V, Valavanis C, van Delft JHM, Steenwinkel PJST, Kyrtopoulos SA: DNA damage and mutagenesis induced by procarbazine in <lambda>lacZ transgenic mice: evidence that bone marrow mutations do not arise primarily through miscoding by O6-methylguanine. Carcinogenesis 1997, 18:2191-2196.

156. Tinwell H, Lefevre PA, Ashby J: Response of the MutaMouse lacZ/galE-transgenic mutation assay to DMN: Comparison with the corresponding Big Blue (lacI) responses. Mutat Res 1994, 307:169-173.

157. Suzuki T, Miyata Y, Saeki K, Kawazoe Y, Hayashi M, Sofuni T: In vivo mutagenesis by the hepatocarcinogen quinoline in the lacZ transgenic mouse: evidence for its in vivo genotoxicity. Mutat Res 1998, 412:161-166.

158. Wang X, Suzuki T, Itoh T, Honna M, Nishikawa A, Fukukawa F, Taka-hashi M, Hayashi M, Kato T, Sofuni T: Specific mutational spectrum of dimethylnitrosamine in Big Blue mice. Environ Mol Mutagen 1996, 28:348-353.

159. Wang X, Suzuki T, Itoh T, Honna M, Nishikawa A, Fukukawa F, Taka-hashi M, Hayashi M, Kato T, Sofuni T: Specific mutational spectrum of dimethylnitrosamine in the lacI transgene of Big Blue ML transgenic mice. Mutat Res 2000, 452:197-210.

160. DFG: <beta>-Propiolacton. In Gesundheitsschädliche Arbeitstoffe: Technisch-arbeitsmedizinische Begründung von MAK-Werten Volume 9, Deutsche Forschungsgemeinschaft (DFG) Weinheim: Wiley-VCH; 1976:1-8.

161. IARC: Phenobarbital (Group 2b). In: IARC: Monographs on the evaluation of carcinogenic risks to humans, Suppl. 7 Lyon: International Agency for Research on Cancer (IARC); 1988:1292-1293.

162. IARC: N,N-Dipropylnitrosamine, CAS: 621-64-7 [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?IRIS]

163. DFG: Beta-Propiolactone. In: Documentation of the Threshold Limit Values (TLV) and Biological Exposure Indices (BEI) Cincinnati (Ohio): American Conference of Governmental Industrial Hygienists (ACGIH); 1998:1292-1293.

164. DFG: Beta-Propiolactone (GENETOX) Beta-Propiolactone, CAS: 57-57-8 [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?GENETOX]

165. DFG: Integrated Risk Information System (IRIS) Quinoline, CAS: 91-22-5 [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?IRIS]

166. IARC: Phenobarbital and phenobarbital sodium. In: IARC: Monographs on the evaluation of carcinogenic risk of chemicals to man, No. 13 Lyon: International Agency for Research on Cancer (IARC); 1977:137-181.

167. DFG: Phenobarbital. In: Integrated Risk Information System (IRIS) N-Nitrosodi-N-propylamine, CAS: 621-64-7 [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?IRIS]

168. DFG: Phenobarbital (Group 2b). In: Integrated Risk Information System (IRIS) N-Nitrosodi-N-propylamine, CAS: 621-64-7 [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?IRIS]

169. DFG: Phenobarbital (Group 2b). In: Phenobarbital (Group 2b). In: Phenobarbital and phenobarbital sodium. In: IARC: Monographs on the evaluation of carcinogenic risk of chemicals to humans, Suppl. 7 Lyon: International Agency for Research on Cancer (IARC); 1987:455-458.

170. IARC: Phenobarbital (Group 2b). In: Phenobarbital and phenobarbital sodium. In: IARC: Monographs on the evaluation of carcinogenic risk of chemicals to humans, Suppl. 7 Lyon: International Agency for Research on Cancer (IARC); 1987:313-315.

171. DFG: Phenobarbital. In: Integrated Risk Information System (IRIS) N-Nitrosodi-N-propylamine, CAS: 621-64-7 [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?IRIS]

172. IARC: Phenobarbital. In: Phenobarbital and phenobarbital sodium. In: IARC: Monographs on the evaluation of carcinogenic risk of chemicals to humans, Suppl. 7 Lyon: International Agency for Research on Cancer (IARC); 1987:313-315.

173. DFG: Phenobarbital. In: Phenobarbital and phenobarbital sodium. In: IARC: Monographs on the evaluation of carcinogenic risk of chemicals to humans, Suppl. 7 Lyon: International Agency for Research on Cancer (IARC); 1987:313-315.

174. DFG: Phenobarbital. In: Phenobarbital and phenobarbital sodium. In: IARC: Monographs on the evaluation of carcinogenic risk of chemicals to humans, Suppl. 7 Lyon: International Agency for Research on Cancer (IARC); 1987:313-315.

175. DFG: Phenobarbital. In: Phenobarbital and phenobarbital sodium. In: IARC: Monographs on the evaluation of carcinogenic risk of chemicals to humans, Suppl. 7 Lyon: International Agency for Research on Cancer (IARC); 1987:313-315.

176. DFG: Phenobarbital. In: Phenobarbital and phenobarbital sodium. In: IARC: Monographs on the evaluation of carcinogenic risk of chemicals to humans, Suppl. 7 Lyon: International Agency for Research on Cancer (IARC); 1987:313-315.

177. DFG: Phenobarbital. In: Phenobarbital and phenobarbital sodium. In: IARC: Monographs on the evaluation of carcinogenic risk of chemicals to humans, Suppl. 7 Lyon: International Agency for Research on Cancer (IARC); 1987:313-315.

178. IARC: Phenobarbital. In: Phenobarbital and phenobarbital sodium. In: IARC: Monographs on the evaluation of carcinogenic risk of chemicals to humans, Suppl. 7 Lyon: International Agency for Research on Cancer (IARC); 1987:313-315.

179. IARC: Phenobarbital. In: Phenobarbital and phenobarbital sodium. In: IARC: Monographs on the evaluation of carcinogenic risk of chemicals to humans, Suppl. 7 Lyon: International Agency for Research on Cancer (IARC); 1987:313-315.

180. IARC: Phenobarbital. In: Phenobarbital and phenobarbital sodium. In: IARC: Monographs on the evaluation of carcinogenic risk of chemicals to humans, Suppl. 7 Lyon: International Agency for Research on Cancer (IARC); 1987:313-315.

181. IARC: Phenobarbital. In: Phenobarbital and phenobarbital sodium. In: IARC: Monographs on the evaluation of carcinogenic risk of chemicals to humans, Suppl. 7 Lyon: International Agency for Research on Cancer (IARC); 1987:313-315.
dibromopropyl)phosphate. *Environ Mol Mutagen* 1996, 28:418-423.

192. IARC: *Urethane*. In *Some anti-thyroid and related substances, nitrofurans and industrial chemicals. Monographs on the evaluation of the carcinogenic risk of chemicals to man*, No.7 Lyon: International Agency for Research on Cancer (IARC); 1974:111-140.

193. Genetic Toxicology (GENETOX) *Urethane, CAS: 51-79-6* [http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?GENETOX]

194. Williams CV, Fletcher K, Tinwell H, Ashby J. Mutagenicity of ethyl carbamate to lacZ-transgenic mice. *Mutagenesis* 1998, 13:133-137.

195. Nohmi T, Suzuki T, Masumura K-I. Recent advances in the protocols of transgenic mouse mutation assays. *Mutat Res* 2000, 455:191-215.

196. Mirsalis J, Monforte J, Winegar R. Transgenic animal models for detection of in vivo mutations. *Annu Rev Pharm Toxicol* 1995, 35:145-164.

197. Heddle JA, Dean S, Nohmi T, Boerrigter M, Casciano D, Douglas GR, Glickman BW, Gorelick NJ, Mirsalis JC, Martus H-J, Skopek TR, Thybaud V, Tindall KR, Yajima N. In vivo transgenic mutation assays. *Environ Mol Mutagen* 2000, 35:253-259.